- Report
- February 2024
- 200 Pages
Global
From €4789EUR$5,000USD£4,048GBP
- Report
- March 2021
- 112 Pages
Global
From €4549EUR$4,750USD£3,845GBP
- Report
- April 2024
- 88 Pages
Global
From €3500EUR$3,915USD£3,062GBP
- Report
- January 2024
- 77 Pages
Global
From €3500EUR$3,915USD£3,062GBP
- Report
- January 2021
- 139 Pages
China, Global
From €3000EUR$3,356USD£2,625GBP
- Report
- June 2024
- 50 Pages
Global
From €2538EUR$2,650USD£2,145GBP
- Report
- March 2022
Global
From €4645EUR$4,850USD£3,926GBP
- Report
- March 2021
Japan, United States, ... Japan, United States, Europe
From €910EUR$950USD£769GBP
- Report
- February 2020
Japan, United States, ... Japan, United States, Europe
From €910EUR$950USD£769GBP
Tobramycin is an aminoglycoside antibiotic used to treat a variety of bacterial infections. It is commonly used to treat respiratory tract infections, urinary tract infections, and skin and soft tissue infections. Tobramycin is also used to treat certain types of meningitis and sepsis. It is usually administered intravenously or intramuscularly, and is available in both generic and branded forms.
Tobramycin is a widely used antibiotic, and is often used in combination with other antibiotics to treat more serious infections. It is generally well tolerated, with few side effects. However, it can cause nephrotoxicity and ototoxicity, and should be used with caution in patients with renal impairment.
The tobramycin market is highly competitive, with a number of companies offering branded and generic versions of the drug. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and Mylan. Show Less Read more